Effects of kidney or kidney-pancreas transplantation on plasma pentosidine  by Hricik, Donald E. et al.
Kidney International, Vol. 43 (1993), pp. 398—403
Effects of kidney or kidney-pancreas transplantation on plasma
pento sidine
DONALD E. HRIcIK, JAMES A. SCHULAK, DAVID R. SELL, JOHN F. FOGARTY,
and VINCENT M. MONNIER
Departments of Medicine and Surgeiy, and the Institute of Pathology, Case Western Reserve University School of Medicine and University
Hospitals of Cleveland, Cleveland, Ohio, USA
Effects of kidney or kidney.pancreas transplantation on plasma pento-
sidine. Tissue and plasma concentrations of pentose-derived glycation
end-products ("pentosidine") are elevated in diabetic patients with
normal renal function and in both diabetic and nondiabetic patients with
end-stage renal disease. To determine the effects of correcting hyper-
glycemia and/or renal failure on the accumulation of pentosidine, we
used reverse phase and ion exchange high performance liquid chroma-
tography to measure this advanced glycation end-product in plasma
proteins of diabetic and nondiabetic transplant recipients at various
time intervals after kidney-pancreas or kidney transplantation. Changes
in plasma pentosidine levels after transplantation were compared to
changes in simultaneously obtained glycohemoglobin levels. Both kid-
ney and kidney-pancreas transplantation were accompanied by a dra-
matic, but incomplete, reduction of plasma pentosidine concentrations
within three months of transplantation. Kidney-pancreas transplanta-
tion resulted in normal glycohemoglobin levels within three months but
offered no advantage over kidney transplantation alone in the partial
correction of plasma pentosidine levels. There was no correlation
between posttransplant plasma pentosidine and glycohemoglobin levels
in either diabetic or nondiabetic transplant recipients. We conclude that
renal failure is the major factor accounting for the accumulation of
pentosidine in both diabetic and nondiabetic patients with end-stage
renal disease. Restoration of euglycemia after kidney-pancreas trans-
plantation provides no additional benefit in reducing plasma pentosidine
levels to that achieved by correction of renal failure after kidney
transplantation alone.
Nonenzymatic glycation of proteins may play an important
role in the pathogenesis of neurovascular complications of
diabetes mellitus. Advanced glycation end-products (AGE),
derived from the interaction of sugars with amino acid residues
of proteins, exhibit a characteristic brown pigmentation and
fluorescence, and can participate in protein-protein cross-link-
ing reactions [1, 2]. AGE-modified proteins may contribute to
the thickening of diabetic basement membranes because, com-
pared to nonglycated proteins, they are less susceptible to
proteolysis and tend to trap other proteins such as albumin and
IgG [1]. AGE-modified proteins are eliminated by macrophages
in a receptor-dependent manner [3, 4] and binding of these
proteins to their receptors promotes the production of cyto-
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kines such as tumor necrosis factor alpha and interleukin- 1 [5].
Skin collagen fluorescence attributed to AGE-modified proteins
has been correlated with the severity of retinopathy, joint
stiffness, and hypertension in patients with insulin-dependent
diabetes mellitus [6].
In patients with diabetes mellitus, nonenzymatic glycation
traditionally has been attributed to elevated concentrations of
glucose. However, recent biochemical analyses of cross-linked
proteins in human extracellular matrix have revealed a new
class of AGE derived from the interaction of a pentose sugar
with arginine and lysine residues of proteins, named "pentosi-
dine" [7]. Compared to normal subjects, elevated concentra-
tions of pentosidine are found in skin collagen of patients with
diabetes mellitus and in both diabetic and nondiabetic patients
with end-stage renal disease (ESRD) [8]. Concentrations of
pentosidine in plasma are also elevated two- to eightfold in
diabetic patients with normal renal function, and up to 22-fold in
both diabetic and nondiabetic patients with ESRD [9]. The
metabolic source of the pentose constituent of pentosidine
remains to be determined. However, in analogy to the use of
glycohemoglobin as an index of cumulative hyperglycemia,
concentrations of plasma pentosidine may reflect cumulative
pentosemia.
Successful pancreas transplantation virtually normalizes glu-
cose tolerance and glycohemoglobin levels in patients with type
I diabetes mellitus [10—12]. In theory, combined kidney-pan-
creas transplantation should normalize plasma pentosidine by
eliminating the two conditions—diabetes mellitus and renal
failure—associated with its accumulation. To test this hypoth-
esis, we measured plasma pentosidine concentrations and gly-
cohemoglobin levels at various times after transplantation in
diabetic patients receiving kidney-pancreas allografts, and com-
pared them to values obtained at comparable intervals after
transplantation in both diabetic and nondiabetic patients receiv-
ing kidney-only allografts.
Methods
Blood samples were obtained for measurement of glycohe-
moglobin, plasma pentosidine, and serum creatinine concentra-
tion on 210 occasions at various time intervals after kidney or
kidney-pancreas transplantation in 128 patients, including 38
diabetic recipients of a kidney-pancreas transplant (DKP), 44
diabetic recipients of a kidney-only transplant (DK), and 46
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nondiabetic recipients of a kidney transplant (NDK). In 26
patients, blood samples were obtained on more than one
occasion. Eighteen diabetic patients (7 kidney and 11 kidney-
pancreas recipients) were studied serially for up to 14 months
after transplantation. Pretranspiant blood specimens, usually
obtained just prior to transplantation, were available in 41
patients (17 DKP, 9 DK, and 15 NDK). Immunosuppression
was comparable in the three groups and generally consisted of
induction therapy with antilymphoblast globulin followed by
maintenance therapy with azathioprine, prednisone, and cyclo-
sporine. A number of patients in this series were withdrawn
from steroid therapy at various intervals after transplantation
such that 36 blood specimens (11 from DKP, 12 from DK, and
13 from NDK) were obtained from steroid-free patients. For
comparison to transplant recipients, plasma pentosidine was
measured in 26 normal volunteers.
For measurement of plasma pentosidine, blood samples were
obtained by venipuncture and collected in EDTA-containing
tubes. After immediate centrifugation, plasma was separated
and frozen to —70°C prior to analysis. Glycohemoglobin was
measured by boronate affinity chromatography in the hemoly-
sate of the same blood samples. The measurements were
performed in the Laboratory of Clinical Chemistry at Univer-
sity Hospitals of Cleveland.
Quantitation of pentosidine by high-performance liquid
chromatography
Plasma protein pentosidine was determined according to the
method of Odetti et al [9]. After acid removal by evaporation,
the hydrolyzed pellet was dissolved in 250 sl water/0.01 M
HFBA and 150 tl, equivalent to 3 mg protein, were injected on
the HPLC connected to a C- 18 column. In order to separate
pentosidine from other fluorescent peaks present in serum, the
pentosidine-containing peak was collected by diverting the flow
with an Automated Switching Valve (Waters) to a LKB model
2112 RediRac fraction collector (Pharmacia LKB Biotechnol-
ogy Inc., Piscataway, New Jersey, USA) loaded with 12 x 75
mm tubes. The gradient controller was programmed such that
the eluate from the column was collected a few minutes before
and a few minutes after peak elution for a total volume of 5 ml
per tube. The contents of each tube was dried by vacuum
centrifugation (Speed-Vac) followed by reconstitution of con-
tents to a total volume of 200 d with 0.02 M sodium acetate
buffer, pH 4.7. A total of 140 jsl was injected into a Protein-Pak
SP SPW 7.5 x 75 mm ion exchange column (Waters) equili-
brated with the same buffer. Elution of pentosidine was
achieved by application of a linear gradient of 0 to 0.06 M NaCl
in the same buffer in 40 minutes. Pentosidine eluted at approx-
imately 22 minutes as monitored by fluorescence at 335 nm
(excitation 385 nm).
Statistical analyses
All data are expressed as mean standard deviation. A
Student's i-test or chi-square analysis was used to compare
clinical characteristics of patients in the three groups. A i-test
also was used to compare plasma pentosidine, glycohemoglobin
and serum creatinine concentrations in the three groups at
various time intervals after transplantation and to compare
plasma pentosidine levels in transplant recipients to those of
Fig. 1. Plasmapentosidineconcentrations (mean SD) atvarious time
intervals after transplantation. Open circles designate diabetic recipi-
ents of kidney-pancreas allografts; closed circles designate diabetic
recipients of kidney-only allografts; closed triangles designate nondia-
betic recipients of kidney allografts. The hatched area represents
plasma pentosidine concentrations (mean 2 sD's) in normal volun-
teers. All mean pentosidine concentrations in the transplant recipients
are greater than those of normal volunteers (P < 0.001).
normal volunteers. Changes in plasma pentosidine and glyco-
hemoglobin levels with time after transplantation were assessed
by analysis of variance. Multiple stepwise linear regression was
used to determine the influence of age, sex, duration of diabetes
mellitus prior to transplantation, time since transplantation,
type of transplant (kidney-only vs. kidney-pancreas) and pred-
nisone dose on plasma pentosidine concentrations which were
found to be distributed normally using a Kolmogorov-Smirnov
goodness of fit test. For the purposes of the multivariate
analysis, only the most recently obtained set of variables was
included for patients whose blood was sampled on more than
one occasion. A P value <0.05 was considered statistically
significant.
Results
Patients receiving kidney-pancreas transplants were signifi-
cantly younger than those receiving kidney-only allografts (33.5
5.3 vs. 39.6 7.3 years, respectively; P < 0.05). The groups
were comparable in the proportion of male patients (47%, DKP;
53%, DK; 52%, NDK). Among diabetic patients, the duration
of diabetes mellitus prior to kidney-pancreas or kidney-only
transplantation also was similar (23.3 5.9 vs. 23.6 4.9 years,
respectively).
Post-transplant blood samples were obtained over a range of
1 to 124 months following transplantation, however, data are
grouped into one of five post-transplant time intervals in Figure
1, which depicts changes in plasma pentosidine concentrations
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Fig. 2. Individual changes in plasma pentosidine concentrations in
prospectively followed diabetic recipients of kidney-pancreas allografts
(A) and diabetic recipients of kidney-only allografts (B) before trans-
plantation and at last follow-up. Open circles, closed circles, closed
triangles, and hatched area have the same designations as in Figure 1.
with time after transplantation. Prior to transplantation, plasma
pentosidine concentrations were elevated 20- to 35-fold in the
three study groups compared to concentrations of 1.3 0.5
pmollmg in normal volunteers. There were no statistically
significant differences in pretransplant pentosidine levels in the
DKP, DK, or NDK groups. Plasma pentosidine concentrations
in each group differed significantly (P < 0.001) from those of
normal volunteers both prior to transplantation and in each of
the five time intervals after transplantation. Analysis of vari-
ance revealed a significant reduction in plasma pentosidine
levels following transplantation in DKP (P < 0.005), DK (P <
0.0001), and NDK (P < 0.01). However, there was no signifi-
cant change in plasma pentosidine beyond the fourth post-
transplant month in either group. Moreover, beyond the fourth
post-transplant month, the plasma pentosidine levels of kidney-
only and kidney-pancreas recipients did not differ significantly.
In patients tested more than two years following transplanta-
tion, mean plasma pentosidine concentration was 4.37 2.0
pmol/mg in DKP (N = 6), 4.7 2.4 pmol/mg in DK (N = 21),
and 3.57 1.3 pmollmg in NDK (N = 12). Figure 2 depicts the
changes in plasma pentosidine with time in 18 diabetic patients
studied serially for up to 14 months following transplantation
and confirms the pattern of a dramatic but incomplete reversal
of elevated plasma pentosidine levels in individual patients.
Changes in glycohemoglobin levels with time after transplan-
tation are shown in Figure 3. In contrast to the persistent
elevation of plasma pentosidine levels in each group, glycohe-
moglobin levels were normal within three months of transplan-
tation in diabetic patients receiving kidney-pancreas transplants
Fig. 3. Glycohemoglobin levels (mean SD) at various time intervals
after transplantation. Open circles, closed circles, and closed triangles
have the same designations as in Figure 1. The shaded area represents
the normal range for glycohemoglobin levels (4 to 8%). * P < 0.01
compared to nondiabetic kidney transplant recipients; ** P < 0.001
compared to nondiabetic kidney transplant recipients and diabetic
kidney-pancreas transplant recipients.
and were comparable to those of nondiabetic kidney transplant
recipients at all post-transplant time intervals. Diabetic patients
receiving kidney-only transplants exhibited elevated glycohe-
moglobin levels at all time intervals after transplantation. Be-
yond the fourth post-transplant month, there were no significant
changes in glycohemoglobin levels within each group. How-
ever, glycohemoglobin levels in the DK group were signifi-
cantly greater than those of the DKP and NDK groups at each
time interval.
There was no significant correlation between plasma pento-
sidine and glycohemoglobin level either in the entire group of
128 patients (r =
—0.02) or in the subgroups (DKP, r = —0.11;
DK, r =
—0.03; NDK, r = 0.07). Multiple stepwise linear
regression demonstrated an independent influence of pred-
nisone dose (P < 0.001) and patient age (P < 0.05) on plasma
pentosidine concentration but indicated no statistically signifi-
cant independent influence of time since transplantation, type
of transplant, sex, duration of diabetes mellitus, glycohemoglo-
bin level, or serum creatinine concentration in plasma pentosi-
dine levels (Table 1). Plasma pentosidine concentrations were
significantly lower in steroid-free patients than in patients
maintained on prednisone (4.9 2.4 vs. 6.9 5.8 pmol/mg,
respectively; P <0.02); however, pentosidine levels in steroid-
free patients remained significantly greater than those of normal
volunteers (P < 0.001).
Discussion
Efforts to delineate the pathophysiologic importance of non-
enzymatic glycation of proteins previously have been hampered
by an inability to quantitate specific glycation end-products. A
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Table 1. Influence of clinical variables on plasma pentosidine
concentration as determined by multiple linear regression
Regression
Variable coefficient T value P value
Prednisone dose mg/kg/day 23.41 6.92 <0.0001
Age years 0.12 2.50 <0.02
Time since transplant months —0.12 —1.62 0.11
Sex 0.04 0.62 0.53
Glycohemoglobin % 0.04 0.50 0.62
Type of transplant 0.01 0.07 0.94
Serum creatinine mg/dl 0.008 0.11 0.95
Multiple R = 0.46; R square = 0.21; F = 40.56; P < 0.0001.
recent study by Makita et a! showed that plasma proteins
recognized by AGE-specific cell-surface receptors are present
in elevated concentrations in patients with diabetes mellitus or
ESRD [13]. In the current study, we used a chemical assay to
demonstrate that at least a portion of the AGEs accumulating in
these disorders are derived from the interaction of plasma
proteins with pentoses. Our results indicate that concentrations
of pentose-derived glycation end-products are increased in the
plasma of both diabetic and nondiabetic patients with ESRD.
Both kidney and kidney-pancreas transplantation result in
dramatic reductions of plasma pentosidine levels in such pa-
tients. However, the correction is incomplete and, more than
two years following transplantation, plasma levels of pentosi-
dine remain elevated more than threefold compared to normal
subjects. Our data also suggest that combined kidney-pancreas
transplantation offers no advantage over kidney transplantation
alone in the partial correction of this novel form of pentose-
derived glycation of plasma proteins. The disparity between the
normal glycohemoglobin levels and the persistent elevation of
plasma pentosidine levels observed after kidney-pancreas
transplantation suggests that a metabolic abnormality leading to
pentose-derived glycation of proteins persists despite restora-
tion of a euglycemic state.
The identity and metabolic source of the pentose responsible
for the generation of pentosidine remain to be determined. In
vitro studies suggest that ribose is more reactive with arginine
and lysine than other pentoses and may be an in vivo precursor
[7]. However, Grandhee and Monnier [14] and Dyer et a! [15]
recently demonstrated that pentosidine can be generated in
vitro from the incubation of proteins with a variety of sugars
including ribose, glucose, fructose, or metabolites of ascorbic
acid. The formation of pentosidine from ribose or glucose may
proceed through a pentosidine intermediate derived from the
respective Amadori products (ribated lysine and glucated ly-
sine; Fig. 4). The possibility of in vivo metabolic conversion of
glucose to pentosidine is obviously relevant to the accumulation
of this glycation end-product in diabetes mellitus. Fructose also
may be implicated in the generation of pentosidine in diabetic
subjects since plasma concentrations of fructose may be ele-
vated as a consequence of activation of the aldose reductase
pathway. A role for ascorbic acid is not excluded since plasma
concentrations of dehydroascorbic acid are elevated at least
twofold in diabetes mellitus [16].
The proposed metabolic pathways in Figure 4 do not readily
explain the elevation of plasma and skin collagen pentosidine
levels in nondiabetic patients with ESRD. Renal failure is
accompanied by glucose intolerance, but it is unlikely that the
resulting mild hyperglycemia can account for the markedly
elevated levels of pentosidine that actually exceed those of
patients with overt diabetes mellitus and normal renal function
[9]. It is possible that, in patients with renal failure, ribonucle-
otide breakdown products and free pentoses are released as a
consequence of increased red blood cell turnover and are
poorly cleared from the plasma by diseased kidneys. The
function of macrophage receptors may be impaired in uremia
[17]. Because AGE-modified proteins are eliminated by macro-
phages in a receptor-dependent manner [3, 4], defective func-
tion of macrophage scavenger receptors also could account for
the accumulation of pentosidine in patients with renal failure.
Although the exact mechanisms responsible for the accumu-
lation of pentosidine in renal failure remain to be determined,
our data suggest that correction of renal failure is more impor-
tant than restoration of euglycemia in reversing elevated plasma
pentosidine levels after kidney-pancreas transplantation. In-
deed, persistent renal insufficiency may account for the mild but
persistent elevation of plasma pentosidine concentrations in
both kidney and kidney-pancreas recipients because these
patients rarely exhibit normal renal function. We were unable,
however, to demonstrate a correlation between plasma pento-
sidine concentration and serum creatinine concentration ip the
posttransplant period. This suggests either that correction of
uremia is achieved faster after transplantation than is the
metabolic abnormality leading to formation of pentosidine or
that factors other than impaired renal function account for the
persistent generation of this AGE. Serum creatinine concentra-
tions provide inaccurate estimates of glomerular filtration rate
in kidney transplant recipients [18]. The use of more accurate
techniques for assessing renal function could shed further light
on the relationship between renal impairment and accumulation
of pentosidine.
Our multivariate analysis demonstrates an independent cor-
relation between plasma pentosidine concentrations and the
dose of prednisone received after transplantation. Zawada et a!
demonstrated that glycated hemoglobin levels were elevated in
nondiabetic renal transplant recipients and attributed their
findings to steroid-induced glucose intolerance [19]. We have
shown that withdrawal of steroid therapy can improve glucose
tolerance and eliminate the need for insulin or oral hypoglyce-
mic agents in patients with overt post-transplant diabetes mel-
litus [20]. If glucose is an in vivo precursor of pentosidine, even
subclinical steroid-induced glucose intolerance could contribute
to the correlation between prednisone dose and plasma pento-
sidine levels in kidney-only transplant recipients, but does not
explain an effect of steroids in kidney-pancreas recipients
whose glycohemoglobin levels are normal. It is possible that
corticosteroids stimulate metabolic pathways leading to pento-
sidine formation or that their catabolic effect enhances the
generation of nonglucose precursors of pentosidine. The inde-
pendent influence of patient age on plasma pentosidine concen-
trations is compatible with the observations of Sell and Mon-
nier, who demonstrated increasing concentrations of tissue
pentosidine concentrations with advancing age [7].
The pathophysiologic importance of advanced glycation end-
products remains to be determined. However, it is tempting to
speculate that pentose-derived glycation end-products could
play a role in the neurovascular complications that are common
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Fig. 4. Proposed metabolic pathways leading
to the generation of pentosidine.
to patients with diabetes mellitus and ESRD. Although this
study demonstrates a dramatic reduction in plasma pentosidine
levels when renal failure is corrected by kidney transplantation,
the persistent three- to fourfold elevation of pentosidine levels
in relatively short-lived plasma proteins probably underesti-
mates the degree of pentose-derived glycation of long-lived
tissue proteins that may play a more direct role in the patho-
genesis of such complications. Thus, our results raise the
disturbing possibility that pentose-derived glycation of proteins
could play a role in persistent neurovascular complications in
both diabetic and nondiabetic patients after otherwise success-
ful kidney-pancreas or kidney transplantation. Our observa-
tions suggest that steroid-sparing immunosuppression regimens
may be beneficial in retarding pentose-derived glycation of
proteins after transplantation. Additional studies are warranted
to determine the correlation between plasma and tissue pento-
side concentrations, to elucidate the mechanisms of pentosidine
accumulation in renal failure, and to clarify the relationship
between this form of advanced glycation and the neurovascular
complications of diabetes mellitus and ESRD.
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